QNCX

insider transactions

Quince Therapeutics, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Grant·A
Jun 11, 26

Christopher J. Senner

Director

$0

2.7K sh

Own New
Grant·A
Jun 11, 26

David Lamond

Director

$0

2.7K sh

Own New
Grant·A
May 18, 26

Brigette Roberts

Chief Corp. Affairs Officer

—

6.8M sh

Own New
Grant·A
May 18, 26

Brigette Roberts

Chief Corp. Affairs Officer

—

2.1M sh

Own New
Grant·A
May 18, 26

Brigette Roberts

Chief Corp. Affairs Officer

—

133.6K sh

Own New
Grant·A
May 18, 26

Brigette Roberts

Chief Corp. Affairs Officer

—

362.1K sh

Own New
Grant·A
May 18, 26

Brigette Roberts

Chief Corp. Affairs Officer

—

69.3K sh

Own New
Grant·A
May 18, 26

Brigette Roberts

Chief Corp. Affairs Officer

—

124.8K sh

Own New
Grant·A
May 18, 26

Brigette Roberts

Chief Corp. Affairs Officer

—

228.9K sh

Own New
Grant·A
May 18, 26

Brigette Roberts

Chief Corp. Affairs Officer

—

34.7K sh

Own New
Grant·A
Jan 23, 26

Dirk Thye KEY

CEO and CMO

$0

1.0M sh

Own New
Grant·A
Jan 23, 26

Charles S. Ryan KEY

President

$0

200.0K sh

Own New
Grant·A
Jan 23, 26

Brendan Hannah

CBO, COO & CCO

$0

365.0K sh

Own New
Grant·A
Jan 2, 26

Christopher J. Senner

Director

$0

21.8K sh

Own New
Grant·A
Jan 2, 26

Margaret Mcloughlin

Director

$0

19.5K sh

Own New
Grant·A
Jan 2, 26

David Lamond

Director

$0

29.4K sh

Own New
Grant·A
Jan 2, 26

June Bray

Director

$0

18.7K sh

Own New

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 11, 2026	Christopher J. Senner	Director	Grant A	2.7K	New	—	$0
Jun 11, 2026	David Lamond	Director	Grant A	2.7K	New	—	$0
May 18, 2026	Brigette Roberts	Chief Corp. Affairs Officer	Grant A	6.8M	New	—	—
May 18, 2026	Brigette Roberts	Chief Corp. Affairs Officer	Grant A	2.1M	New	—	—
May 18, 2026	Brigette Roberts	Chief Corp. Affairs Officer	Grant A	133.6K	New	—	—
May 18, 2026	Brigette Roberts	Chief Corp. Affairs Officer	Grant A	362.1K	New	—	—
May 18, 2026	Brigette Roberts	Chief Corp. Affairs Officer	Grant A	69.3K	New	—	—
May 18, 2026	Brigette Roberts	Chief Corp. Affairs Officer	Grant A	124.8K	New	—	—
May 18, 2026	Brigette Roberts	Chief Corp. Affairs Officer	Grant A	228.9K	New	—	—
May 18, 2026	Brigette Roberts	Chief Corp. Affairs Officer	Grant A	34.7K	New	—	—
Jan 23, 2026	Dirk Thye KEY	CEO and CMO	Grant A	1.0M	New	—	$0
Jan 23, 2026	Charles S. Ryan KEY	President	Grant A	200.0K	New	—	$0
Jan 23, 2026	Brendan Hannah	CBO, COO & CCO	Grant A	365.0K	New	—	$0
Jan 2, 2026	Christopher J. Senner	Director	Grant A	21.8K	New	—	$0
Jan 2, 2026	Margaret Mcloughlin	Director	Grant A	19.5K	New	—	$0
Jan 2, 2026	David Lamond	Director	Grant A	29.4K	New	—	$0
Jan 2, 2026	June Bray	Director	Grant A	18.7K	New	—	$0

About QNCX insider trading

This page tracks insider transactions for Quince Therapeutics, Inc. (QNCX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.